| Name | Title | Contact Details |
|---|
The executive search industry is ripe for change. True disruption needs vision and courage. It needs a firm filled with people who are not just willing to change but who want to be the very ones to leave their fingerprints on the transformation itself. Kingsley Gate Partners is a global executive search consulting firm founded with one vision in mind - to transform the world of executive search. Our partnership spans over five continents with completed searches in over 30 countries. Our mission and value proposition is simple: more Accurate, higher Velocity search by ensuring that our consultants are armed with mobile-first, cloud-based tools that help them give our clients differentiated insight on candidates. Businesses are evolving at an incredible pace, and so are their leadership needs. Our experienced consultants fuse their credible expert insight with science and technology to solve complex human capital/talent challenges. Our proprietary Synchronous Fit® 3.0 framework is architected, designed, and built to exponentially enhance the search success metrics required by our clients and includes our two online structured tools - the Attribute Selector and Athena - that highlight the leadership/management attributes and motivators that our clients desire in the ideal candidate. Our clients have transparent, real-time access to the stack-ranked candidates within each search via ClientSuite, an interactive mobile portal that allows our clients up-to-the-second search status in the palm of their hand.
Culinda is a cyber-security company specialized in securing medical loT devices using the latest technologies and our extensive expertise.
City Color is a Dallas, TX-based company in the Business Services sector.
Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering. The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.
Run the most profitable practice, compete with corporate practices, and increase your income. Get the best possible price for your dental supplies.